Scholarlink

Background <p>Mucopolysaccharidosis type I (MPS I) is an inherited lysosomal storage disorder (LSD) caused by recessive mutations in the α-L-iduronidase (<i>IDUA</i>) gene. Enzyme replacement therapy (ERT) utilizing terminal mannose-6-phosphate (M6P)-carrying <i>N</i>-glycans attached to therapeutic enzymes produced by mammalian cell lines has been clinically applied to several LSDs. Recent studies suggested an unidentified delivery pathway mediated by sialic acid-containing <i>N</i>-glycans. However, more economical platform development is required to produce large quantities of recombinant enzymes. Transgenic silkworms have been established as low-cost systems for expressing recombinant glycoproteins. Microbial endo-β-<i>N</i>-acetylglucosaminidases (ENGases) enable the transglycosylation of <i>N</i>-glycans to other types.</p> Methods <p>We purified recombinant human IDUA from <i>IDUA</i> transgenic silkworm cocoons and performed ENGase-mediated transglycosylation. Furthermore, we performed intravenous enzyme replacement therapy in a Japanese macaque MPS I non-human primate model carrying a homozygous <i>IDUA</i> missense mutation.</p> Results <p>Here we show the establishment of <i>IDUA</i> transgenic silkworms and purification of recombinant human IDUA from cocoons. As M6P- and sialic acid-containing <i>N</i>-glycans are not attached to purified hIDUA, we perform ENGase-mediated transglycosylation to obtain hIDUAs with M6P- and sialic acid-containing <i>N</i>-glycans (neoglyco-hIDUAs). Furthermore, we perform intravenous neoglyco-hIDUA replacement therapy in MPS I non-human primate model and succeed in improving the clinical signs and reducing the urinary glycosaminoglycan (GAG) levels.</p> Conclusions <p>These glycotechnologies using transgenic silkworms and ENGases are expected to serve as platforms for developing therapeutic glycoproteins.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

N-glycan-modified α-L-iduronidase produced by transgenic silkworms ameliorates clinical signs in a Japanese macaque with mucopolysaccharidosis I

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月18日

查看全文
  • Chika Shinoda,
  • Keisuke Kitakaze,
  • Yuya Sasai,
  • So-Ichiro Nishioka,
  • Isao Kobayashi,
  • Megumi Sumitani,
  • Ken-Ichiro Tatematsu,
  • Tetsuya Iizuka,
  • Akira Harazono,
  • Ai Mitani,
  • Akihisa Kaneko,
  • Masanori Imamura,
  • Takako Miyabe-Nishiwaki,
  • Yasuhiro Go,
  • Akihiro Hirata,
  • Yoshie Takeuchi,
  • Teru Mizuno,
  • Kei Kiriyama,
  • Jun Tsukimoto,
  • Satomi Nadanaka,
  • Akiko Ishii-Watabe,
  • Takashi Kinoshita,
  • Hiroshi Kitagawa,
  • Yasuyuki Suzuki,
  • Takao Oishi,
  • Hideki Sezutsu,
  • Kohji Itoh

摘要

Background

Mucopolysaccharidosis type I (MPS I) is an inherited lysosomal storage disorder (LSD) caused by recessive mutations in the α-L-iduronidase (IDUA) gene. Enzyme replacement therapy (ERT) utilizing terminal mannose-6-phosphate (M6P)-carrying N-glycans attached to therapeutic enzymes produced by mammalian cell lines has been clinically applied to several LSDs. Recent studies suggested an unidentified delivery pathway mediated by sialic acid-containing N-glycans. However, more economical platform development is required to produce large quantities of recombinant enzymes. Transgenic silkworms have been established as low-cost systems for expressing recombinant glycoproteins. Microbial endo-β-N-acetylglucosaminidases (ENGases) enable the transglycosylation of N-glycans to other types.

Methods

We purified recombinant human IDUA from IDUA transgenic silkworm cocoons and performed ENGase-mediated transglycosylation. Furthermore, we performed intravenous enzyme replacement therapy in a Japanese macaque MPS I non-human primate model carrying a homozygous IDUA missense mutation.

Results

Here we show the establishment of IDUA transgenic silkworms and purification of recombinant human IDUA from cocoons. As M6P- and sialic acid-containing N-glycans are not attached to purified hIDUA, we perform ENGase-mediated transglycosylation to obtain hIDUAs with M6P- and sialic acid-containing N-glycans (neoglyco-hIDUAs). Furthermore, we perform intravenous neoglyco-hIDUA replacement therapy in MPS I non-human primate model and succeed in improving the clinical signs and reducing the urinary glycosaminoglycan (GAG) levels.

Conclusions

These glycotechnologies using transgenic silkworms and ENGases are expected to serve as platforms for developing therapeutic glycoproteins.